Celgene生物制藥公司

2012年排名： 91

連續(xù)上榜時(shí)間：4年

????完成幾宗大手筆收購后，這家總部位于新澤西州薩米特的生物制藥公司在2011年繼續(xù)保持增長。Celgene2009年首次上榜，排名第22。此后，該公司每年都躋身“財(cái)富增長最快的公司排行榜”，努力成為腫瘤醫(yī)療行業(yè)的領(lǐng)頭羊。

????Celgene治療血液和骨髓疾病的熱銷藥Revlimid 和Vidaza取得了巨大的成功，繼續(xù)推動公司大踏步發(fā)展。2011年，公司營業(yè)收入同比增長34%，達(dá)到了約48億美元。

????但公司也遇到了一些挫折。該公司一直在爭取讓血癌藥Revlimid能在歐洲擴(kuò)大使用范圍，但最近撤回了申請，令投資者十分意外。這種藥物已經(jīng)在歐洲和美國獲準(zhǔn)用于治療多發(fā)性骨髓瘤，但Celgene一直在尋求將這種藥物更早地提供給骨髓瘤患者，并將它作為維持療法。

Celgene

2012 Fastest-Growing rank: 91

Years on list: 4

????Coming off a few major acquisitions, the Summit, NJ-based biopharmaceutical company continued to gain in 2011. Celgene first made it onto this list in 2009, coming in at No. 22. Since then, it has continued to be among the Fortune's fastest growing companies every year as the company works to become an oncology leader.

????Celgene continued winning with the successes of popular drugs Revlimid and Vidaza for blood and bone marrow conditions. For 2011, revenues rose by 34% to approximately $4.8 billion over the previous year.

????The company has seen some setbacks, however. It has been trying to win approval in Europe to widen use of blood cancer drug Revlimid, but withdrew its application recently in a move that stunned investors. The drug is already approved in Europe and the U.S. to treat multiple myeloma, but Celgene has been seeking to offer the treatment sooner to myeloma patients and as a maintenance therapy.